Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503451 | 1.00 | DUT (0.36) | DUTMEN1KMT2ADHFRSLC28A1 | |
| SCHEMBL22984005 | 0.83 | DHFR (0.52) | DHFR | |
| SCHEMBL16964189 | 0.83 | DHFR (0.52) | DHFR | |
| SCHEMBL2431876 | 0.83 | DHFR (0.52) | DHFR | |
| SCHEMBL8514886 | 0.82 | TK1 (0.46) | DHFR | |
| SCHEMBL15782468 | 0.81 | SLC28A1 (0.32) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL860749 | 0.81 | SLC28A1 (0.32) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL10238922 | 0.81 | SLC28A1 (0.32) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17807707 | 0.81 | SLC28A1 (0.32) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL19250917 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394331-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-8841275-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142626-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | DUT, NT5C2, NUDT21 | DUT 1/4885MEN1 2832/4885KMT2A 1357/4885 |
| US-20120142626-A1 | COMPOUNDS | HAVCR2, EIF2AK2, NTPCR | DUT 20/4885MEN1 3988/4885KMT2A 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.